看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 4.9x - 5.4x | 5.1x |
| Historical Pb Multiple | 4.5x - 10.2x | 7.4x |
| Fair Value | HK$ 15.68 - HK$ 17.33 | HK$ 16.50 |
| Upside | -3.1% - 7.1% | 2.0% |
| Benchmarks | - | Full Ticker |
| Shanghai Henlius Biotech, Inc. | 269,600.0% | SEHK:2696 |
| Innovent Biologics, Inc. | 180,100.0% | SEHK:1801 |
| Akeso, Inc. | 992,600.0% | SEHK:9926 |
| BeiGene, Ltd. | 616,000.0% | SEHK:6160 |
| Jiangsu Hengrui Medicine Co., Ltd. | 60,027,600.0% | SHSE:600276 |
| Shanghai Junshi Biosciences Co., Ltd. | 187,700.0% | SEHK:1877 |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| 2696 | 1801 | 9926 | 6160 | 600276 | 1877 | |||
| SEHK:2696 | SEHK:1801 | SEHK:9926 | SEHK:6160 | SHSE:600276 | SEHK:1877 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | 3.5% | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | 11.8% | NM- | ||
| Latest Twelve Months | 50.3% | 90.8% | -125.4% | 26.9% | 47.3% | 43.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -101.5% | -41.2% | -571.2% | -182.3% | 20.0% | -108.8% | ||
| Prior Fiscal Year | 10.1% | -16.6% | 44.8% | -35.9% | 18.9% | -152.0% | ||
| Latest Fiscal Year | 14.3% | -1.0% | -24.2% | -16.9% | 22.6% | -65.7% | ||
| Latest Twelve Months | 14.3% | -1.0% | -24.2% | -16.9% | 22.6% | -65.7% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -13.7% | -17.5% | -14.4% | -38.0% | 15.5% | -24.8% | ||
| Prior Fiscal Year | 28.5% | -8.8% | 55.4% | -22.3% | 11.0% | -27.5% | ||
| Latest Twelve Months | 31.5% | -0.7% | -8.9% | -18.8% | 14.7% | -19.7% | ||
| Next Fiscal Year | 22.0% | 2.9% | 3.9% | 3.5% | 14.7% | -20.4% | ||
| Two Fiscal Years Forward | 18.1% | 9.5% | 14.6% | 15.9% | 14.2% | -23.6% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 2.9x | 8.2x | 34.0x | 7.5x | 11.6x | 14.1x | ||
| Price / LTM EPS | 20.5x | -814.4x | -140.4x | -44.1x | 51.2x | -21.4x | ||
| Price / Book | 5.6x | 5.9x | 10.6x | 8.5x | 7.1x | 4.7x | ||
| Price / Fwd Book | 4.5x | 5.7x | 10.2x | 7.9x | 6.3x | 6.2x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 5.6x | 7.1x | 10.6x | |||||
| Historical P/B Ratio | 4.5x | 7.4x | 10.2x | |||||
| Selected P/B Multiple | 4.9x | 5.1x | 5.4x | |||||
| (x) Book Value | 5,860 | 5,860 | 5,860 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 2696 | 1801 | 9926 | 6160 | 600276 | 1877 | |
| Value of Common Equity | 16,825 | 77,106 | 72,218 | 27,179 | 324,541 | 29,345 | |
| (/) Shares Outstanding | 543.5 | 1,638.2 | 897.6 | 1,297.0 | 6,358.6 | 1,936.3 | |
| Implied Stock Price | 30.96 | 47.07 | 80.46 | 20.96 | 51.04 | 15.16 | |
| FX Conversion Rate to Trading Currency | 0.94 | 0.94 | 0.94 | 0.13 | 1.00 | 0.94 | |
| Implied Stock Price (Trading Cur) | 33.05 | 50.25 | 85.90 | 162.90 | 51.04 | 16.18 | |
| Trading Currency | HKD | HKD | HKD | HKD | CNY | HKD | |
| FX Rate to Reporting Currency | 0.94 | 0.94 | 0.94 | 0.13 | 1.00 | 0.94 | |